Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Dose Increase in Pediatric ADHD
NCT00485407Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: ADHD Symptom Response. Started Jul 2003; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00485407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485407.